Compare YELP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YELP | DSGN |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 853.8M |
| IPO Year | 2011 | 2021 |
| Metric | YELP | DSGN |
|---|---|---|
| Price | $18.99 | $10.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $23.75 | $21.71 |
| AVG Volume (30 Days) | ★ 1.2M | 458.9K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.15 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $1,464,955,000.00 | N/A |
| Revenue This Year | $0.11 | N/A |
| Revenue Next Year | $3.02 | N/A |
| P/E Ratio | $21.97 | ★ N/A |
| Revenue Growth | ★ 3.75 | N/A |
| 52 Week Low | $17.27 | $6.16 |
| 52 Week High | $34.49 | $17.25 |
| Indicator | YELP | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 41.75 |
| Support Level | $17.27 | $9.78 |
| Resistance Level | $23.99 | $11.44 |
| Average True Range (ATR) | 0.83 | 0.65 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 37.92 | 56.05 |
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making appropriate buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States, and also has its presence in other countries.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.